Poppy power

Philip Larkin examines the last of his transgenic poppies growing in a greenhouse at the Black Mountain Laboratory in Canberra, Australia. Credit: Courtesy of Brendan Borrell" />Philip Larkin examines the last of his transgenic poppies growing in a greenhouse at the Black Mountain Laboratory in Canberra, Australia. Credit: Courtesy of Brendan Borrell Out of a dozen transgenic plants in Philip Larkin's greenhouse at Black Mountain Laboratory in Canberra, only two sho

Written byBrendan Borrell
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Out of a dozen transgenic plants in Philip Larkin's greenhouse at Black Mountain Laboratory in Canberra, only two show any signs of life. These bulbous, green flower buds are all that remain of a productive line of research. The other plants are withered and yellow like corn stalks, crackling to the touch. "They look pretty cruddy, don't they?" Larkin says, during an overcast November day. "I'm obviously disappointed." Larkin, a plant geneticist at the Commonwealth Scientific and Industrial Research Organization, hasn't called it quits yet. If these poppies don't end up in your drug store, they may well end up in your gas tank.

It's a little known fact that since the 1950s, the island of Tasmania has supplied as much as 40% of the world's medicinal morphine. A handful of Tasmanian companies are licensed to grow the opium poppy, Papaver somniferum; Tasmanian Alkaloids, a wholly owned subsidiary of Johnson ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies